Share the post

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma

Email

Facebook

Twitter

Subscribe to Business News

Get updates delivered right to your inbox!

Thank you for your subscription

Please follow the link we've just sent you to activate the subscription.